Literature DB >> 18177354

Cyclophosphamide for anti-GAD antibody-positive refractory status epilepticus.

Ines C Kanter1, Hagen B Huttner, Dimitre Staykov, Teresa Biermann, Tobias Struffert, Frank Kerling, Max-Josef Hilz, Peter D Schellinger, Stefan Schwab, Jürgen Bardutzky.   

Abstract

Glutamic acid decarboxylase (GAD) is the enzyme which catalyzes the production of gamma aminobutyric acid (GABA), the main inhibitory neurotransmitter in the central nervous system (CNS). There is increasing evidence that severe GAD autoimmunity may be associated with refractory epilepsy. Immunomodulation and GABAergic drugs have been suggested as treatment options. We report here for the first time on a patient with sudden onset of refractory status epilepticus in the presence of strong intrathecal anti-GAD antibody synthesis who was successfully treated with cyclophosphamide, and give an overview of available data on epilepsy associated with GAD autoimmunity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18177354     DOI: 10.1111/j.1528-1167.2007.01500.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  14 in total

Review 1.  Diabetes and epilepsy in children and adolescents.

Authors:  M Loredana Marcovecchio; Marianna Immacolata Petrosino; Francesco Chiarelli
Journal:  Curr Diab Rep       Date:  2015-04       Impact factor: 4.810

2.  Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms.

Authors:  Amer Awad; Olaf Stüve
Journal:  Ther Adv Neurol Disord       Date:  2009-11       Impact factor: 6.570

3.  Paraneoplastic neurological syndromes: general treatment overview.

Authors:  Aurélien Viaccoz; Jérôme Honnorat
Journal:  Curr Treat Options Neurol       Date:  2013-04       Impact factor: 3.598

Review 4.  Aggressive multiple sclerosis: proposed definition and treatment algorithm.

Authors:  Carolina A Rush; Heather J MacLean; Mark S Freedman
Journal:  Nat Rev Neurol       Date:  2015-06-02       Impact factor: 42.937

5.  Evaluation of positive and negative predictors of seizure outcomes among patients with immune-mediated epilepsy: a meta-analysis.

Authors:  Divyanshu Dubey; Zehra Farzal; Ryan Hays; L Steven Brown; Steven Vernino
Journal:  Ther Adv Neurol Disord       Date:  2016-07-04       Impact factor: 6.570

Review 6.  Temporal lobe epilepsy and anti glutamic acid decarboxylase autoimmunity.

Authors:  Luca Errichiello; Salvatore Striano; Federico Zara; Pasquale Striano
Journal:  Neurol Sci       Date:  2011-04-06       Impact factor: 3.307

7.  Limbic encephalitis and related cortical syndromes.

Authors:  Ignacio Rubio-Agusti; Miguel Salavert; Luis Bataller
Journal:  Curr Treat Options Neurol       Date:  2013-04       Impact factor: 3.598

8.  Epilepsia partialis continua in type 1 diabetes: evolution into epileptic encephalopathy with continuous spike-waves during slow sleep.

Authors:  Maria Giuseppina Baglietto; Maria Margherita Mancardi; Alessandro Giannattasio; Nicola Minuto; Andrea Rossi; Giuseppe Capovilla; Edvige Veneselli; Renata Lorini; Giuseppe d'Annunzio
Journal:  Neurol Sci       Date:  2009-08-15       Impact factor: 3.307

9.  An Update on the Treatment of Pediatric Autoimmune Encephalitis.

Authors:  Cory Stingl; Kathleen Cardinale; Heather Van Mater
Journal:  Curr Treatm Opt Rheumatol       Date:  2018-02-17

10.  The growing spectrum of antibody-associated inflammatory brain diseases in children.

Authors:  Sandra Bigi; Manisha Hladio; Marinka Twilt; Josep Dalmau; Susanne M Benseler
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2015-04-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.